364 related articles for article (PubMed ID: 25696919)
21. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
22. Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of
Walker AR; Byrd JC; Blachly JS; Bhatnagar B; Mims AS; Orwick S; Lin TL; Crosswell HE; Zhang D; Minden MD; Munugalavadla V; Long L; Liu J; Pan Y; Oellerich T; Serve H; Rao AV; Blum WG
Clin Cancer Res; 2020 Nov; 26(22):5852-5859. PubMed ID: 32820015
[TBL] [Abstract][Full Text] [Related]
23. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
24. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study.
Izutsu K; Ando K; Ennishi D; Shibayama H; Suzumiya J; Yamamoto K; Ichikawa S; Kato K; Kumagai K; Patel P; Iizumi S; Hayashi N; Kawasumi H; Murayama K; Nagai H
Cancer Sci; 2021 Jun; 112(6):2405-2415. PubMed ID: 33728735
[TBL] [Abstract][Full Text] [Related]
25. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
27. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
[TBL] [Abstract][Full Text] [Related]
28. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Spurgeon SE; Coffey G; Fletcher LB; Burke R; Tyner JW; Druker BJ; Betz A; DeGuzman F; Pak Y; Baker D; Pandey A; Hollenbach SJ; Sinha U; Loriaux MM
J Pharmacol Exp Ther; 2013 Feb; 344(2):378-87. PubMed ID: 23220742
[TBL] [Abstract][Full Text] [Related]
29. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
30. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
Davids MS; Brown JR
Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Munakata W; Ando K; Hatake K; Fukuhara N; Kinoshita T; Fukuhara S; Shirasugi Y; Yokoyama M; Ichikawa S; Ohmachi K; Gion N; Aoi A; Tobinai K
Cancer Sci; 2019 May; 110(5):1686-1694. PubMed ID: 30815927
[TBL] [Abstract][Full Text] [Related]
32. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Jaglowski SM; Jones JA; Nagar V; Flynn JM; Andritsos LA; Maddocks KJ; Woyach JA; Blum KA; Grever MR; Smucker K; Ruppert AS; Heerema NA; Lozanski G; Stefanos M; Munneke B; West JS; Neuenburg JK; James DF; Hall N; Johnson AJ; Byrd JC
Blood; 2015 Aug; 126(7):842-50. PubMed ID: 26116658
[TBL] [Abstract][Full Text] [Related]
33. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
34. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
35. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
Brown JR; Hamadani M; Hayslip J; Janssens A; Wagner-Johnston N; Ottmann O; Arnason J; Tilly H; Millenson M; Offner F; Gabrail NY; Ganguly S; Ailawadhi S; Kasar S; Kater AP; Doorduijn JK; Gao L; Lager JJ; Wu B; Egile C; Kersten MJ
Lancet Haematol; 2018 Apr; 5(4):e170-e180. PubMed ID: 29550382
[TBL] [Abstract][Full Text] [Related]
36. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
37. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
39. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P
Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405
[TBL] [Abstract][Full Text] [Related]
40. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
